{"source":"kalshi","id":"KXDTX401-27","ticker":"KXDTX401-27","slug":"KXDTX401-27","title":"FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)","description":null,"image":null,"icon":null,"active":true,"closed":false,"start_date":"2026-06-17T21:00:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":null,"volume":90.04,"volume_24hr":0.0,"volume_24h_change":null,"normalized_vol_24hr":null,"normalized_volume":5.774473190307617,"liquidity":null,"open_interest":15.01,"categories":["Finance"],"tags":[],"synthetic":false,"is_group":false,"group_key":null,"parent_event_id":null,"probability":null,"spread":null,"top_outcome":"a full approval or an accelerated approval","top_outcome_probability":0.62,"top_outcome_prob_24h_change":0.0,"top_outcome_volume_24h_change":0.0,"updated_at":"2026-06-23T01:06:01.087138Z","fetched_at":"2026-06-23T01:06:01.087138Z","added_at":"2026-06-17T21:13:38.461385Z","url":"https://kalshi.com/markets/kxdtx401/fda-decision-dtx401-pariglasgene-brecaparvovec-by-ultragenyx-pharmaceutical-in-2026/kxdtx401-27","chart_24h":null,"markets":[{"source":"kalshi","id":"KXDTX401-27-Y","event_id":"KXDTX401-27","slug":"KXDTX401-27-Y","question":"What will the FDA's decision be on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026?","group_item_title":"a full approval or an accelerated approval","description":"If the FDA's decision on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026 is a full approval or an accelerated approval, the market resolves to Yes.\n\n---\n\nThis market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. \n\nDTX401 (pariglasgene brecaparvovec) is a one-time gene therapy developed by Ultragenyx Pharmaceutical to treat Glycogen Storage Disease Type Ia (GSDIa), a rare inherited disorder in which the liver cannot properly release stored sugar into the bloodstream. Think of it like installing a corrected instruction manual inside liver cells: after a single infusion, the therapy is designed to restore the missing enzyme activity — glucose-6-phosphatase — so the liver can once again regulate blood sugar on its own. In the Phase 3 GlucoGene trial , DTX401 produced a statistically significant 41.3% mean reduction in daily cornstarch intake at Week 48 versus 10.3% for placebo (p<0.0001), with durability data at 96 weeks showing approximately 60–61% reductions.","image":null,"icon":null,"outcomes":["Yes","No"],"outcome_prices":[0.62,0.38],"probability":0.62,"spread":0.050000000000000044,"active":true,"closed":false,"start_date":"2026-06-17T21:00:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":"2027-01-01T04:59:00Z","volume":90.04,"volume_24hr":0.0,"prob_24h_change":0.0,"volume_24h_change":0.0,"normalized_vol_24hr":null,"normalized_volume":6.019169330596924,"liquidity":null,"categories":["Finance"],"countries":["United States"],"updated_at":"2026-07-02T20:38:18.942735Z","fetched_at":"2026-07-02T20:38:18.942735Z","added_at":"2026-06-17T21:13:38.591203Z","url":"https://kalshi.com/markets/kxdtx401/fda-decision-dtx401-pariglasgene-brecaparvovec-by-ultragenyx-pharmaceutical-in-2026/kxdtx401-27","event_title":"FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)","chart_24h":[0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62]}],"_meta":{"attribution":"pdata.world — aggregated prediction-market data across 8 platforms","canonical_url":"https://pdata.world/events/kalshi/KXDTX401-27","as_of":"2026-07-03T02:15:57.886584Z","docs":"https://api.pdata.world/docs","cite_as":"According to pdata.world (tracking Kalshi): \"FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)\" — top market at 62% probability across 1 outcome","source_url":null}}